论文部分内容阅读
单克隆抗体的特异性在导向药物治疗某些疾病的应用研究中起着重要的作用。尽管单克隆抗体对靶细胞具有特异性识别能力,但仍可能与一些无关细胞有着不同程度的交叉反应。本实验结果表明:(1)用浓度为10~(-8)M、10~(-9)M 的抗普通型急性淋巴细胞白血病单克隆抗体免疫毒素(79:ricin)处理骨髓细胞后,CFU-GM 的增殖分别受到抑制.(2)用79单克隆抗体阻断后,抑制作用明显减弱.(3)去除骨髓中79抗体阳细胞后,CFU-GM 的增殖也明显减弱。这表明79单克隆抗体不仅仅是一个识别普通型急性淋巴细胞白血病细胞的单克隆抗体,它还可能是一个识别部分骨髓粒单系造血祖细胞的单克隆抗体。
The specificity of the monoclonal antibody plays an important role in the study of the application of the guide drug in the treatment of certain diseases. Although monoclonal antibodies have a specific ability to recognize target cells, they may still cross-react with some unrelated cells to varying degrees. The results of this experiment showed that: (1) After treatment of myeloid cells with anti-common acute lymphoblastic leukemia monoclonal antibody immunotoxin (79: ricin) at concentrations of 10 -8 M and 10 -9 M, CFU -GM were inhibited respectively. (2) After blocking with 79 monoclonal antibody, the inhibitory effect was obviously weakened. (3) The proliferation of CFU-GM was obviously weakened after removing 79 antibody positive cells in bone marrow. This suggests that monoclonal antibody 79 is not only a monoclonal antibody that recognizes normal acute lymphoblastic leukemia cells but may also be a monoclonal antibody that recognizes part of myelomonocytic hematopoietic progenitor cells.